Tag: pharmaceuticals

SAN DIEGO, July 08, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), have until Monday, August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges Rocket Pharmaceuticals as well as one of Rocket Pharmaceuticals’ top executives with violations of the Securities Exchange Act of 1934.

Florida, July 08, 2025 (GLOBE NEWSWIRE) -- Slate, a leading innovation discovery platform developed by GreyB, has announced the launch of “Prism", a new structured research module to solve complex, constraint-based R&D challenges. Slate Prism breaks down your query, scans thousands of patents and papers, and delivers evidence-backed insights on what works, what doesn’t, and why. It goes beyond simple search results to deliver in-depth analysis of solutions.

Corbion, a global leader in sustainable ingredient solutions, has successfully secured multiple regulatory approvals from China’s General Administration of Customs (GACC) paving the way for offering Corbion’s high quality, sustainable, algae-derived omega-3 DHA solutions in China’s fast-growing human and animal nutrition segments.

NEW YORK, July 05, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), of the important August 11, 2025 lead plaintiff deadline.

Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its second novel orexin receptor 2 (OX2R) agonist, following the recent clearance of an Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) for a Phase 1 clinical study of ORX142 in healthy volunteers. (click here).

München, Deutschland, 04. Juli 2025 – Das Komitee des Strüngmann Award gab heute bekannt, dass Dr. Dragan Grabulovski, Dr. Philipp Spycher und Dr. Isabella Attinger-Toller, die Gründer von Araris Biotech, als die diesjährigen Preisträger ausgezeichnet wurden. Der Award verfolgt das Ziel, herausragende unternehmerische und wissenschaftliche Leistungen sowie bahnbrechende Ideen in der Life-Science-Branche zu fördern. Das Gründerteam von Araris Biotech überzeugte nicht nur durch die Entwicklung einer neuartigen Technologie im Bereich der Antikörper-Wirkstoff-Konjugate, sondern auch durch deren erfolgreiche Validierung in Form von Partnerschaften und einem präklinischen Exit. Diese neue Medikamentenklasse hat das Potenzial, maßgeblich zur Weiterentwicklung zielgerichteter Krebstherapien beizutragen und somit einen Mehrwert für Menschen mit Krebserkrankungen weltweit zu erreichen. 

Munich, Germany, July 04, 2025 – The Strüngmann Award selection committee today announced that Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D., the founders of Araris Biotech, have been honored as this year’s winners. The award aims to support outstanding entrepreneurial and scientific achievements, as well as ground-breaking ideas in the life sciences industry. Araris Biotech’s founding team distinguished itself not only by developing of a novel technology in the antibody-drug conjugates (ADCs) field, but also by successfully validating this innovation through partnerships and a preclinical exit. This new drug class has the potential to significantly advance the development of targeted cancer therapies, thereby delivering added value for people living with cancer worldwide.